Related Experiment Videos
Transforming growth factor beta in Alzheimer's disease
1Neuroimmunobiology and Host Defense Laboratory, Minneapolis Medical Research Foundation, MN 55404, USA.
Clinical and Diagnostic Laboratory Immunology
|January 1, 1994
Summary
Transforming growth factor beta (TGF-beta) may protect against Alzheimer's disease (AD) inflammation. Elevated TGF-beta levels were observed in AD patients, suggesting a potential protective response to neuronal injury in Alzheimer's disease.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Alzheimer's disease (AD) is increasingly viewed as an inflammatory condition.
- Anti-inflammatory cytokines, like transforming growth factor beta (TGF-beta), may counteract this inflammation.
- Investigating TGF-beta's role could reveal new therapeutic targets for AD.
Purpose of the Study:
- To investigate the levels of TGF-beta in Alzheimer's disease patients.
- To determine if TGF-beta plays a protective role in the inflammatory processes of AD.
- To correlate TGF-beta levels with disease status.
Main Methods:
- Collected cerebrospinal fluid (CSF) and serum samples from Alzheimer's disease patients.
- Measured TGF-beta levels in both CSF and serum samples.
- Analyzed TGF-beta levels in samples obtained shortly after death and in pre-mortem serum.
Main Results:
- Transforming growth factor beta (TGF-beta) levels were elevated in both cerebrospinal fluid and serum of AD patients post-mortem.
- Serum TGF-beta levels were also significantly elevated in AD patients before death.
- These findings indicate a consistent elevation of TGF-beta in Alzheimer's disease.
Conclusions:
- Elevated TGF-beta levels in Alzheimer's disease may indicate a protective host response.
- The findings suggest TGF-beta could be involved in mitigating immunologically mediated neuronal injury in AD.
- Further research into TGF-beta's therapeutic potential for Alzheimer's disease is warranted.